STRATIGOS, A. J.; SEKULIC, A.; PERIS, K.; BECHTER, O.; PREY, S.; KAATZ, M.; LEWIS, K. D.; BASSET-SEGUIN, N.; CHANG, A. L. S.; DALLE, S.; ORLAND, A. F.; LICITRA, L.; ROBERT, C.; ULRICH, C.; HAUSCHILD, A.; MIGDEN, M. R.; DUMMER, R.; YOO, S.-Y.; COATES, E.; OKOYE, E.; BASSUKAS, I.; LOQUAI, C.; DE GIORGI, V.; EROGLU, Z.; GUTZMER, R.; ULRICH, J.; PUIG, S.; SEEBACH, F.; LOWY, I.; FURY, M. G. Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 2, p. s178, 2023. DOI: 10.25251/skin.7.supp.178. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/2000. Acesso em: 4 jul. 2024.